Physician profile
John S Alspaugh
NPI 1063527505
$7,714.66
in general payments reported to CMS, 2019-2025
20 companies · $1,428 in 2025
The $1,428 reported for 2025 was more than what 79% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $897 · 2020: $1,547 · 2021: $953 · 2022: $1,070 · 2023: $585 · 2024: $1,234 · 2025: $1,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,944 · Long Term Medical Supply Or Device Loan: $1,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,944.23 |
| Long Term Medical Supply Or Device Loan | $1,303.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Musculoskeletal Transplant Foundation INC. | $2,181.06 | 2019-2025 | |
| Allergan, INC. | $1,633.94 | 2019-2022 | |
| Integra Lifesciences Corporation | $1,376.08 | 2024-2025 | Durasorb Monofilament Mesh, Integra, Surgimend |
| Abbvie INC. | $1,153.26 | 2023-2025 | Natrelle Saline-Filled Breast Implants, Botox |
| Mentor Worldwide LLC | $430.57 | 2019-2023 | Mentor Memorygel Resterilizable Gel Sizer |
| Galderma Laboratories, L.P. | $287.71 | 2021-2025 | |
| Sientra, INC. | $188.89 | 2020-2022 | |
| Revance Therapeutics, INC. | $70.59 | 2024-2025 | Daxxify |
| Medela LLC | $64.42 | 2020-2021 | |
| Bard Peripheral Vascular, INC. | $59.27 | 2021 | |
| Merz North America, INC. | $47.41 | 2019-2024 | |
| Medtronic, INC. | $44.23 | 2021 | |
| Kerecis Limited | $35.93 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $32.84 | 2025 | |
| Bioventus LLC | $22.53 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tei Biosciences INC | $19.05 | 2019 | |
| Tela Bio, INC. | $18.76 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Smith+Nephew, INC. | $16.81 | 2022 | |
| Mimedx Group, INC. | $15.85 | 2025 | |
| Innovation Technologies INC | $15.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Alspaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.